AbbVie (NYSE: ABBV) has consistently raised its quarterly dividend since its spin-off from Abbott Laboratories in 2013, overcoming the significant challenge of losing patent exclusivity for its flagship drug, Humira. The pharmaceutical company has effectively countered declining Humira sales with the successful launches of Skyrizi and Rinvoq, which are projected to boost revenue from $31 billion in 2025 to around $50 billion by 2030. Additionally, AbbVie’s neuroscience portfolio, including products like Vraylar and Botox Therapeutic, is contributing to steady revenue growth.
The recent 5.5% increase in AbbVie’s quarterly dividend to $1.73 per share reflects its strong earnings outlook, with forecasts predicting a 45.4% earnings increase in 2026. This positions AbbVie favorably for future dividend growth and total returns, despite its current valuation being higher than some peers in the pharmaceutical sector.
For market professionals, AbbVie’s ability to navigate patent challenges while maintaining robust growth in new drug sales suggests a compelling opportunity for both income and capital appreciation in the coming years.
Source: fool.com